Physician profile
Robert E Behan
NPI 1275547416
$3,688.11
in general payments reported to CMS, 2019-2025
19 companies · $953 in 2025
The $953 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $76.39 · 2021: $354 · 2022: $810 · 2023: $679 · 2024: $533 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.02 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $752.63 | 2021-2025 | Cequa, Xelpros |
| Abbvie INC. | $499.43 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Bausch & Lomb Americas INC. | $410.39 | 2022-2025 | Miebo, Vyzulta, Infuse |
| Tarsus Pharmaceuticals, INC. | $329.84 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $303.30 | 2019-2025 | Tryptyr, Precision 1, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.35 | 2019-2021 | |
| Oyster Point Pharma, INC. | $236.33 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $138.91 | 2022-2023 | Tearcare System |
| Harrow Eye, LLC | $137.76 | 2024-2025 | Vevye |
| Allergan, INC. | $124.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $107.90 | 2019-2022 | |
| Coopervision INC. | $90.39 | 2022-2025 | Onefit Contact Lens |
| Johnson & Johnson Vision Care, INC. | $86.74 | 2022-2025 | |
| Biotissue Holdings INC. | $58.30 | 2021 | |
| Dompe US, INC. | $46.73 | 2022-2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $43.91 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $38.70 | 2019 | |
| Leadiant Biosciences, INC. | $24.23 | 2019 | |
| Shire North American Group INC | $21.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Behan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.